MRK - IMV to advance its lead asset with Keytruda in mid-stage blood cancer study

Following the feedback from the FDA, IMV ([[IMV]] -2.2%) in agreement with Merck ([[MRK]] +0.4%) is set to evaluate maveropepimut-S (DPX-Survivac) in combination with Keytruda in recurrent/refractory diffuse large B cell lymphoma (r/rDLBCL).Maveropepimut-S, an experimental immunotherapy, is IMV’s lead candidate and Keytruda is an FDA approved anti-PD-1 therapy from Merck.The randomized two-stage trial involving 150 subjects will comprise three-arms. Maveropepimut-S and Keytruda combination will be evaluated with or without cyclophosphamide (“CPA”) to test the latter’s effect as an activator of the immune response.A third arm will assess maveropepimut-S as a single agent. The primary objective of the trial is Objective Response Rate (“ORR”).With Q4 2020 financial results, IMV announced it was finalizing the protocol of the Phase 2b clinical study after receiving feedback from the FDA.

For further details see:

IMV to advance its lead asset with Keytruda in mid-stage blood cancer study